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Abstract
Aims/hypothesis We aimed to compare diabetic retinopathy outcomes in people with type 1 diabetes following introduction of
continuous subcutaneous insulin infusion (CSII) therapy with outcomes in people receiving continuing therapy with multiple
daily insulin injections (MDI).
Methods This is a retrospective cohort study using the Scottish Care Information – Diabetes database for retinal screening
outcomes and HbA1c changes in 204 adults commenced on CSII therapy between 2013 and 2016, and 211 adults eligible for
CSII during the same period but who continued on MDI therapy. Diabetic retinopathy progression (time to minimum one-grade
worsening in diabetic retinopathy from baseline grading) was plotted for CSII and MDI cohorts using Kaplan–Meier curves, and
outcomes were compared using multivariate Cox regression analysis adjusting for age, sex, baseline HbA1c, blood pressure,
cholesterol, smoking status and socioeconomic quintile. Impact of baseline HbA1c and change in HbA1c on diabetic retinopathy
progression was assessed within CSII and MDI cohorts.
Results CSII participants were significantly younger, were from less socially deprived areas, and had lower HbA1c and higher diastolic
BP at baseline. There was a larger reduction in HbA1c at 1 year in those on CSII vs MDI (−6 mmol/mol [−0.6%] vs −2 mmol/mol
[−0.2%], p< 0.01). Diabetic retinopathy progression occurred in a smaller proportion of adults following commencement of CSII vs
continued MDI therapy over mean 2.3 year follow-up (26.5% vs 18.6%, p = 0.0097). High baseline HbA1c (75 mmol/mol [9%]) was
associated with diabetic retinopathy progression in the MDI group (p= 0.0049) but not the CSII group (p = 0.93). Change in HbA1c at
follow-up, irrespective of baseline glycaemic status, did not significantly affect diabetic retinopathy progression in either group.
Conclusions/interpretation CSII was associated with reduced diabetic retinopathy progression compared with continuedMDI therapy,
and may be protective against diabetic retinopathy progression for those with high baseline HbA1c. Progression of diabetic retinopathy
over 3 years was not associated with a change in HbA1c.
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Diabetic retinopathy is one of the leading causes of blindness
worldwide [1], and prevalence rises with age [2]. It has been
well established, following the landmark DCCT, that good
glycaemic control confers long-term benefits to reduce the
risk of developing diabetic retinopathy [3]. However,
concerns remain that rapid improvements in blood glucose
level precipitate transient worsening of diabetic retinopathy
[4], and many guidelines recommend controlled improve-
ments in glycaemic targets with increased monitoring for reti-
nopathy in the initial stages when treatment is altered [5].
In order to optimise glycaemic targets, insulin is typically
delivered either via multiple daily insulin injections (MDI) or
by continuous subcutaneous insulin infusion (CSII). A recent
Cochrane review suggested that CSII is associated with a small
but significant improvement in glycaemic control vs MDI ther-
apy (0.3% absolute reduction in HbA1c) [6]. However, relative-
ly few studies have evaluated whether treatment with CSII
confers any benefits over MDI in reducing long-term diabetic
retinopathy risk in an adult population, or whether there is any
increased risk of early diabetic retinopathyworsening following
a change in treatment from MDI to CSII.
Early studies assessing diabetic retinopathy progression
following the introduction of CSII typically showed no
improvement or deterioration of diabetic retinopathy with
CSII [7, 8]. However, study numbers were small, participants
were selected for CSII due to poor glycaemic control on
conventional therapy and suitable comparator groups were not
used. In addition, early insulin pump systems used in many
previous study populations were more cumbersome as they
did not have the ability to pre-programme variable basal rates
and lacked safety alarms to notify users about infusion prob-
lems. A more recent study in adolescents suggests that CSII is
associated with lower rates of retinopathy than MDI [9].
Our main aim in this study was to investigate retinopathy
outcomes in adults with type 1 diabetes following the intro-
duction of CSII therapy compared with those who continued
on therapy with MDI using a robust clinical database system.
Methods
Study participants Participants were identified from three
diabetes centres within NHS Lothian, Scotland, using the
Scottish Care Information – Diabetes (SCI-Diabetes) data-
base, which links clinical information for all registered people
with diabetes in Scotland using electronic care records in
primary care, hospitals and pharmacies.
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Diabetes records were reviewed for all participants with
type 1 diabetes who were commenced on CSII therapy
between 1 January 2013 and 1 December 2016 (N = 293).
Retinal data collected during annual retinopathy screening
for these participants were reviewed from 1 January 2011 to
1 December 2018. Within NHS Lothian, a 5 day structured
education course on carbohydrate counting and diabetes
management is recommended prior to referral for CSII thera-
py. To identify a control MDI group who had received a
similar level of diabetes education to the CSII group, people
who completed this course at a similar time to the CSII partic-
ipants, but who remained on MDI therapy, were recruited for
comparison (N = 277).
People were included if they were aged >16 years; had
documented type 1 diabetes, defined as a clinical diagnosis
of type 1 diabetes with no evidence in the historical record of
>6 months between diagnosis and insulin requirement; and
had no history of use of oral hypoglycaemic drug treatment
other than adjuvant metformin. All participants were on treat-
ment with either CSII or MDI therapy and were participating
in the Scottish diabetes retinopathy screening programme
during the study period. People were excluded if the date of
commencing CSII therapy or completion of diabetes educa-
tion could not be verified; if baseline or follow-up retinal
images had not been taken, or those taken were deemed
ungradable for both eyes; if they had been suspended from
the retinal screening programme for assessment and potential
treatment at ophthalmology clinics; or if they had the maxi-
mum severity retinopathy grading (R4) at baseline and could
not therefore ‘progress’ to a higher diabetic retinopathy sever-
ity grade.
The study was approved by the South East Scotland Ethics
Committee and NHS Lothian Caldicott Guardian, and was
conducted according to the principles of the Declaration of
Helsinki.
Study design This was a retrospective cohort study using
routine clinical and diabetes retinal screening data. Data
were extracted from SCI-Diabetes, including up-to-date
information on retinal screening records, HbA1c, mode
of current insulin therapy and diabetes education histo-
ry, and anthropometric, metabolic and demographic data
(weight, BMI, blood pressure, cholesterol, smoking
history and an area-based measure of socioeconomic
deprivation).
Study time Study entry (time = 0) for the CSII group was the
date of commencing CSII therapy. Mean lag time from
completing the recommended structured diabetes education
course to commencing CSII therapy was 945 days (median
841 days, IQR 333–1555 days). Study entry for the MDI
group was calculated as 945 days from the date of comple-
tion of the diabetes education course to give an equivalent
entry time to the CSII group using the mean lag time
from education to CSII commencement. Secondary analy-
ses calculating study entry as 841 days from the date of
completion of the diabetes education course were also
completed using the median lag time from education to
CSII commencement, and results for these analyses can be
found in the electronic supplementary material (ESM).
Study exit for CSII and MDI groups was taken as the
earliest occurring of any of the following: a retinal event,
emigration from Scotland, death or the end of the study
period on 1 December 2018.
Retinopathy assessment Diabetic retinopathy assessment was
performed as part of the Scottish diabetes retinal screening
programme. A single macula-centred photograph is taken for
each eye every 6 to 12 months and retinopathy grading
assessed using the Scottish Diabetic Retinopathy Grading
Scheme (SDRGS) [10] by experienced SDRGS-qualified
graders. Severity of diabetic retinopathy was classified as: 0,
no diabetic retinopathy; 1, mild background diabetic retinop-
athy; 2, moderate observable diabetic retinopathy; 3, referable
diabetic retinopathy; or 4, proliferative diabetic retinopathy
[10]. Repeatability of image grading was not assessed; howev-
er, these are the same data that are used to inform clinical
decision making for further retinal assessment. Images were
also assigned a maculopathy grading based on whether
markers of macular oedema were present. For accurate assess-
ment for the presence of macular oedema, 3D imaging, usual-
ly using ocular coherence tomography (OCT), is required as
false positives are common from 2D fundus images. As such,
this study focused on retinopathy gradings rather than
maculopathy gradings.
As retinopathy gradings were available for both eyes, the
more severe grading was used as the baseline grading.
The diabetic retinopathy screening assessment immediate-
ly prior to the study entry date was taken as the baseline
grading (median 71 [IQR 18–243] days prior to study entry
date).
Retinopathy progression was defined as a minimum one-
grade worsening in either eye from the baseline grading.
Assessment of glycaemic control by HbA1c For each partici-
pant, HbA1c data were extracted from the SCI-Diabetes data-
base. Timings of baseline and follow-up HbA1c values relative
to the time of study entry were variable. The HbA1c value
immediately prior to the study entry date was taken as the
baseline HbA1c (median 75 [IQR 27–172] days prior to study
entry date). Subsequent follow-up HbA1c readings for each
individual were identified for each subsequent 6 month period
where available. Where multiple HbA1c readings had been
taken within a 6 month period, the HbA1c value closest to,
but not exceeding, the 6 month timepoint was used as the
HbA1c value for that interval. Mean study HbA1c over 3 year
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follow-up was estimated by calculating the mean HbA1c from
the 6-monthly values for each individual. The HbA1c at
approximately 1 year post study entry was also recorded, with
a range of 8 to 20 months from study entry accepted as the
1 year HbA1c value in cases where 12 month values were not
available. Study exit HbA1c was recorded as the last available
HbA1c value recorded after 20 months from study entry.
Statistical analyses Baseline variables including age, sex,
diabetes duration, baseline HbA1c, socioeconomic status
(assessed using quintile of Scottish Index of Multiple
Deprivation [SIMD] score [11]) and diastolic BP were
summarised as median with IQR for continuous data and as
percentage for categorical data. In the CSII vs MDI groups,
baseline demographic and metabolic data were compared
using the unpaired t test for continuous normally distributed
data and χ2 test or Fisher’s exact test for categorical data.
Kaplan–Meier plots were used to assess time to an event
corresponding to retinopathy progression or exit from the
study for another reason (death, emigration, end of study peri-
od) in CSII and MDI groups, with calculation of statistical
differences between groups using the logrank test. Groups
Patients eligible during
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Fig. 1 Flow chart showing number of people assessed and analysed for CSII and MDI groups and exclusions
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were not matched, but characteristics were similar between the
groups and potential confounders were included as covariates
in Cox proportional hazard analyses. Univariate and multivar-
iate Cox proportional hazards analyses were performed using
the following covariates: CSII or MDI treatment group, age,
sex, diabetes duration, baseline HbA1c, systolic BP, diastolic
BP, cholesterol, creatinine, SIMD, smoking status and base-
line diabetic retinopathy grading.
To assess the impact of baseline, mean study, 1 year and
study exit HbA1c, participants were stratified using HbA1c
values (<58 mmol/mol [<7.5%]), 58–75 mmol/mol [7.5–
9%] and >75 mmol/mol [>9%]) and compared using
Kaplan–Meier plots as above. Similarly, to assess the impact
of the change in HbA1c at 1 year, participants were stratified
using change in HbA1c value (>−5 mmol [>−0.5%], −5 to
5 mmol/mol [−0.5 to 0.5%] and >5 mmol/mol [>0.5%]
change) and compared using Kaplan–Meier plots as above.
Statistical significancewas assumed for p < 0.05. Statistical
analyses were completed using R version 3.4.1 (https://www.
R-project.org/.)
Results
Study populations Between 1 January 2013 and 1 December
2016, 293 people with type 1 diabetes who commenced CSII
therapy were identified. Of these, 89 were excluded: 23 were
aged <16 years at commencement of CSII, 23 had no available
baseline and/or follow-up graded retinal screening results, 31
had been excluded from screening for further ophthalmology
assessment or treatment, three had the maximum severity reti-
nopathy grading at baseline and for a further nine we were not
able to verify if the dates for commencing CSII were correct.
The remaining 204 were included in the analysis (Fig. 1).
We identified 277 MDI control participants who had
completed structured diabetes education at a similar time to
the CSII cohort but who did not proceed to CSII therapy,
largely due to patient preference. Of these, 66 were excluded:
34 had no available baseline and/or follow-up graded retinal
screening results, 28 had been excluded from screening for
further ophthalmology assessment or treatment, one had the
maximum severity grading at baseline and for a further three
Table 1 Baseline demographics





Age at diagnosis (years) 15 (10–26) 21 (12–33) <0.001
Age at study entry (years) 38 (29–48) 43 (31–53) <0.001
Diabetes duration (years) 18 (11–25) 16 (8–27) 0.63
Sex M:F (%M) 76:128 (37.3) 90:121 (42.7) 0.31
Weight (kg) 78.9 (67.6–90.3) 79.5 (67.6–91.5) 0.84
BMI (kg/m2) 26.9 (24.0–31.2) 27.1 (24.2–30.4) 0.97
HbA1c (mmol/mol) 66 (58–74) 67 (60–80) <0.05
HbA1c (%) 8.2 (7.5–8.9) 8.3 (7.6–9.5) <0.05
SIMD 4 (3–5) 3 (2–5) <0.05
Cholesterol (mmol/l) 4.7 (4.2–5.2) 4.8 (4.2–5.4) 0.14
Creatinine (μmol/l) 73 (67–83) 74 (68–84) 0.26
Systolic BP (mm/Hg) 128 (118–140) 128 (120–138) 0.95
Diastolic BP (mm/Hg) 78 (73–84) 77 (71–83) <0.001
Smoking status 0.20
Non-smoker 141 (69) 131 (62)
Ex-smoker 48 (24) 55 (26)
Current smoker 15 (7) 25 (12)
Baseline diabetic retinopathy grading 0.10
R0 93 (45.6) 100 (47.4)
R1 109 (53.4) 101 (47.9)
R2 0 2 (0.9)
R3 2 (1.0) 8 (3.8)
R4 Excluded Excluded
Data are median (IQR) or number (%) unless otherwise indicated. p values were calculated using unpaired t test
for continuous numerical data and χ2 test or Fisher’s exact test for categorical data. Baseline grading indicates the
overall baseline retinopathy grading for each individual. As retinal data were available for both eyes, the more
severe retinal grading outcome for that individual was used as the baseline
F, female; M, male
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we were not able to verify if the dates for diabetes education
were correct. The remaining 211 were included in the analysis
(Fig. 1).
Baseline demographic and metabolic data are shown in
Table 1. CSII participants were significantly younger, with
earlier age of diabetes diagnosis, lower baseline HbA1c, higher
diastolic BP and with lower proportions of people in more
deprived socioeconomic quintiles. The majority of partici-
pants had either no diabetic retinopathy or mild diabetic reti-
nopathy at baseline. There were no significant differences in
baseline diabetic retinopathy gradings between CSII vs MDI
cohorts.
HbA1c changes in CSII and MDI The median number of 6-
monthly HbA1c values per person collected over a 3 year
study interval was 5 (IQR 4–6). There was a small but statis-
tically significant difference in baseline HbA1c (CSII
66 mmol/mol [8.2%] vs MDI 67 mmol/mol [8.3%],
p < 0.01). In the CSII group, there were significant reductions
in mean study HbA1c (62 mmol/mol [7.8%]), 1 year HbA1c
(59 mmol/mol [7.5%]) and study exit HbA1c (61 mmol/mol
[7.7%]) from baseline (all p < 0.001). In contrast, there were
no significant changes in mean study HbA1c, 1 year HbA1c or
study exit HbA1c (all 67 mmol/mol [8.3%]) from baseline in
the MDI group. At all follow-up timepoints, CSII participants
had a significantly lower HbA1c than MDI participants
(p < 0.001), and a greater HbA1c reduction (1 year:
−6 mmol/mol [−0.6%] vs −1 mmol/mol [−0.1%], p < 0.01;
study exit: −4 mmol/mol [−0.4%] vs −2 mmol/mol [−0.2%],
p = 0.12). In both groups, univariate regression analysis
showed higher baseline HbA1c was significantly associated
with greater reductions in HbA1c at 1 year (p < 0.0001).
The distribution of HbA1c in the CSII and MDI groups is
shown in Table 2. There was a higher proportion of MDI vs
CSII participants in the highest baseline HbA1c group
(>75 mmol/mol [>9%]) but differences were not statistically
significant (Table 2). Follow-up HbA1c in CSII and MDI
groups at 1 year increased by 5 mmol/mol (0.5%) in 11.1%
vs 18.1% and decreased by more than 5 mmol/mol (0.5%) in
51.9% vs 29.3% (p < 0.001; Table 2). Changes at study exit
showed a similar pattern between MDI and CSII groups,
though numbers of participants with available data for analy-
sis were lower (p = 0.03; Table 2).
Table 2 Stratified HbA1c analysis





Baseline HbA1c (/total n with data) /193 /209 0.06
<58 mmol/mol (<7.5%), n (%) 42 (21.8) 44 (21.1)
58–75 mmol/mol (7.5–9%), n (%) 107 (55.4) 96 (45.9)
>75 mmol/mol (>9%), n (%) 44 (22.8) 69 (33)
Change in HbA1c at 1 year (/total n with data) /189 /188 <0.001
>−5 mmol/mol (>−0.5%), n (%) 98 (51.9) 55 (29.3)
−5 to 5 mmol/mol (−0.5 to 0.5%), n (%) 70 (37.0) 99 (52.7)
>5 mmol/mol (>0.5%), n (%) 21 (11.1) 34 (18.1)
Change in HbA1c at study exit (/total n with data) /142 /124 0.03
>−5 mmol/mol (>−0.5%), n (%) 63 (44.4) 36 (29.0)
−5 to 5 mmol/mol (−0.5 to 0.5%), n (%) 58 (40.8) 61 (49.2)
>5 mmol/mol (>0.5%), n (%) 21 (14.8) 27 (21.8)
Table showing numbers of all participants stratified to subgroups for baseline HbA1c and change in HbA1c at
1 year and study exit. p values comparing subgroups for all CSII andMDI ormatched CSII andMDI cohorts were
calculated using χ2 test
Fig. 2 Retinopathy in comparator treatment groups (a) and HbA1c
subgroups (b–e). Kaplan–Meier survival plots compare event-free
survival rates in CSII/MDI treatment groups (a) and HbA1c subgroups
(b–e). An event corresponds to diabetic retinopathy progression and was
defined as a minimum one-grade worsening in either eye from the
baseline grading. Vertical dashes indicate participants who were
censored due to incomplete 3 year follow-up. (a) Comparison of CSII
(blue) and MDI (red) participants for the entire cohort. CSII was
associated with significantly reduced retinopathy progression over 3
years compared with MDI (p=0.0097). (b, c) Comparison of
participants with baseline HbA1c <58 mmol/mol (7.5%) (low: lilac),
58–75 mmol/mol (7.5–9%) (middle: blue) or >75 mmol/mol (9%)
(high: red) in the CSII group (b) and the MDI group (c). High baseline
HbA1c (>75 mmol/mol [9%]) was associated with increased diabetic
retinopathy progression in the MDI group (p=0.0049) but was not a
determinant of diabetic retinopathy progression in the CSII group
(p=0.93). (d, e) Comparison of unmatched participants with change in
HbA1c at 1 year of less than −5mmol/mol (0.5%) (decrease: lilac), −5 to 5
mmol/mol (0.5 to 0.5%) (stable: blue) or more than 5 mmol/mol (0.5%)
(increase: red) in the CSII group (d) and the MDI group (e). Change in
HbA1c at follow-up did not significantly impact diabetic retinopathy
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Retinopathy events in CSII vs MDI Kaplan–Meier curves
describing time to a diabetic retinopathy progression event
for comparator groups are shown in Fig. 2a–e. Mean follow-
up for the entire cohort was 839 days (2.3 years), with diabetic
retinopathy progression occurring in 38 participants (18.6%)
in the CSII group vs 56 participants (26.5%) in theMDI group
(Fig. 2a; p = 0.0097). Of these, unilateral retinal progression
was identified in 21/56 (37.5%) people in the MDI group vs
14/38 (36.8%) people in the CSII group, while the rest had
bilateral retinal progression.
Pump participants had a reduced risk of diabetic retinopa-
thy progression on univariate (HR 0.58, p = 0.01) and multi-
variate (HR 0.56, p = 0.02) Cox proportional hazards analysis,
adjusting for age, sex, diabetes duration, baseline HbA1c, BP,
cholesterol, creatinine, SIMD, smoking status and baseline
diabetic retinopathy grading (Table 3).
Those with mild retinopathy at baseline were also at low
risk of progression (HR 0.07), with the majority of events
occurring in those with no baseline retinopathy (76/94,
80.9%). Older age was also associated with reduced risk of
diabetic retinopathy progression (HR 0.97), though longer
diabetes duration (HR 1.03), increased creatinine (HR 1.01)
and history of previous smoking (HR 1.89) were associated
with increased diabetic retinopathy progression risk on multi-
variate analysis.
Higher baseline HbA1c was associated with increased
diabetic retinopathy progression risk for the entire cohort on
univariate and multivariate analyses (HR 1.03, p < 0.001;
Table 3). However, this effect was driven by the MDI cohort,
with baseline HbA1c having no significant impact on the
frequency of diabetic retinopathy progression occurring in
the CSII cohort (Fig. 2b; p = 0.93), while in the MDI cohort
HbA1c >75 mmol/mol (>9%) was associated with a signifi-
cantly higher proportion of participants with diabetic retinop-
athy progression (28/69 participants, 40.6%) than those with
HbA1c <58 mmol/mol (<7.5%) (6/44 participants, 13.6%)
(Fig. 2c; p = 0.0049). The same outcomes were found when
groups were stratified by mean study HbA1c, with no signifi-
cant impact of high mean study HbA1c on diabetic retinopathy
progression noted in the CSII cohort (p = 0.26), while high
mean study HbA1c was associated with increased diabetic
retinopathy progression in the MDI cohort (p = 0.023).
HbA1c values at 1 year and study exit showed no significant
impact on the frequency of diabetic retinopathy progression in
either cohort. Change in HbA1c at 1 year from baseline was
not associated with diabetic retinopathy progression in either
cohort (CSII: Fig. 2d [p = 0.19], MDI: Fig. 2e [p = 0.21]).
Discussion
In this real-world study, using a robust clinical database and a
nationalised single diabetic retinopathy scoring system, we
observed that CSII therapy was associated with significantly
Table 3 Hazard ratios for covari-
ates on univariate and multivari-
ate Cox proportional hazards
analysis
Covariate Univariate analysis Multivariate analysis
HR (95% CI) p value HR (95% CI) p value
Pump group 0.58 0.39, 0.88 0.01 0.56 0.34, 0.91 0.02
Age at study entry 0.98 0.96, 0.99 0.99 0.97 0.96, 0.99 <0.01
Male sex 0.84 0.55, 1.29 0.43 0.69 0.40, 1.19 0.18
Diabetes duration 1.00 0.98, 1.01 0.65 1.03 1.02, 1.05 <0.001
Baseline HbA1c 1.03 1.01, 1.03 <0.001 1.03 1.01, 1.04 <0.001
Systolic 1.00 0.98, 1.01 0.68 1.00 0.98, 1.02 0.92
Diastolic 0.99 0.97, 1.02 0.61 1.01 0.99, 1.04 0.36
Cholesterol 0.97 0.78, 1.22 0.82 0.94 0.73, 1.21 0.62
Creatinine 1.00 0.99, 1.01 0.87 1.01 1.00, 1.02 0.01
SIMD 0.89 0.77, 1.03 0.13 0.94 0.79, 1.12 0.51
Smoking status
Non-smoker 1.00 (Ref.) 1.00 (Ref.)
Ex-smoker 1.54 0.98, 2.41 0.06 1.89 1.13, 3.17 0.02
Current smoker 1.60 0.84, 3.08 0.15 0.94 0.43, 2.07 0.88
Baseline diabetic retinopathy grading
R0 1.00 (Ref.) 1.00 (Ref.)
R1 0.11 0.06, 0.20 <0.001 0.07 0.03, 0.13 <0.001
R2 5.43 1.32, 22.32 0.02 2.90 0.62, 13.6 0.18
R3 1.04 0.38, 2.84 0.94 0.28 0.09, 0.86 0.03
Ref., reference
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lower diabetic retinopathy progression over a 3 year follow-up
period in adults with type 1 diabetes who had completed struc-
tured diabetes education than in those on MDI therapy who
had completed an equivalent structured diabetes education
programme (18.6% in CSII vs 26.5% in MDI, p = 0.0097).
In addition, there was no evidence of early diabetic retinopa-
thy worsening in those using CSII compared with MDI over
the first 18 months. This is despite significantly larger reduc-
tions in HbA1c in the CSII group (6 mmol/mol [0.5%] reduc-
tion) vs the MDI group (1 mmol/mol [0.1%] reduction) at
1 year post study entry (p < 0.001). Findings were confirmed
on multivariate analysis adjusting for multiple potential
confounders.
Those with longer duration of diabetes were found to be at
higher risk of diabetic retinopathy progression, which was
expected as this is a well-established risk factor for diabetic
retinopathy [1]. Surprisingly, older age was associated with a
small but significant reduction in risk of diabetic retinopathy
progression in our cohort. This was driven by MDI partici-
pants, with no significant effect of age on diabetic retinopathy
progressionwhenCSII participants were analysed in isolation.
The addition of drug therapies such as statins and antihyper-
tensives in older participants may have contributed to diabetic
retinopathy risk reduction; however, we were unable to assess
this in our cohort.
Studies of diabetic retinopathy progression in adults are
lacking in real-world settings. However, our findings are
consistent with a longitudinal study of adolescents (aged 12–
20 years) treated with either CSII or MDI therapy over a period
of 15 years [9]. The study showed a significantly lower risk of
developing retinopathy in those treated with CSII vs MDI (OR
0.66), though the majority of assessments (79%) were from
participants who were only reviewed once during the study
period. Proportions of people developing retinopathy were
slightly lower than in our cohort (17% in CSII, 22% in MDI);
however, this is likely to be consistent with a patient cohort of
younger age and shorter diabetes duration than in our study. A
further study assessed retinal changes in 31 adults following
initiation of CSII using a range of imagingmodalities, including
OCT, and showed stable retinal characteristics over 1 year with
no evidence of early diabetic retinopathy worsening [12].
High baseline HbA1c (75 mmol/mol [>9%]) was associated
with increased diabetic retinopathy progression in the MDI
group. In contrast, diabetic retinopathy progression in the
CSII group was not found to be associated with baseline
HbA1c. In the MDI group there were no significant reductions
in follow-up HbA1c values when compared with baseline
levels. However, in the CSII group, follow-up HbA1c values
were significantly reduced from baseline, and were lower than
HbA1c levels assessed at the same timepoints in the MDI
group. Absolute change in HbA1c at 1 year from baseline
was not significantly associated with diabetic retinopathy
progression for either group.
We hypothesise that factors intrinsic to CSII therapy are
protective against diabetic retinopathy progression in those
with high baseline HbA1c, while those with high baseline
HbA1c on MDI remain at increased diabetic retinopathy risk.
Many of the MDI participants did not achieve a substantial
reduction in HbA1c on follow-up and therefore had continued
exposure to high glycaemic levels which may have contribut-
ed to increased diabetic retinopathy risk. This is supported by
the fact that high mean study HbA1c was significantly associ-
ated with diabetic retinopathy progression in the MDI group,
though this was not true in the CSII group.
While exposure to high glycaemic levels is a well-
established risk factor for diabetic retinopathy, recurrent
disabling hypoglycaemia may also increase diabetic retinopa-
thy risk [13]. Though recurrent disabling hypoglycaemia is a
possible indication for consideration of CSII therapy, it was
not possible for this to be accurately assessed within our
cohorts and levels of hypoglycaemia within the groups may
have differed. It is therefore possible that some of those
perceived to have good glycaemic control, reflected by a
lower baseline HbA1c, were exposed to higher levels of
hypoglycaemia prior to the study period, which could have
contributed to increased diabetic retinopathy risk. CSII thera-
py has been shown to reduce frequency of hypoglycaemia
[14], which may also have conferred a benefit in terms of
diabetic retinopathy risk, even in those with no HbA1c
reduction.
Other factors related to better control of diabetes (including
glycaemic variability [GV], discussed further below) may also
have contributed to the reduction in diabetic retinopathy
observed in the CSII group.
It is important to note that, within our retinopathy screening
programme in Scotland, when people are commenced on CSII
therapy, recommendations are in place with regard to modifi-
cations to early HbA1c targets where appropriate, particularly
for those with high baseline HbA1c levels, and improved
surveillance for retinopathy [5]. As such, the reductions in
HbA1c, although significant in our study, may have been
achieved more gradually in the CSII group, and may have
facilitated improved retinopathy outcomes.
Glycaemic control as measured by HbA1c has been shown
to be important in reducing diabetic retinopathy progression,
as evidenced from the DCCT study [15]. However, other stud-
ies do not demonstrate an association between baseline
HbA1c, or change in HbA1c, and diabetic retinopathy progres-
sion following initiation of CSII therapy [16]. Evidence from
the DCCT also showed that HbA1c changes did not fully
explain the risk of diabetic retinopathy progression in type 1
diabetes, and that other features of glucose control, such as the
extent of postprandial glucose excursions or counterregulatory
responses to hypoglycaemia, which are not easily reflected by
a summary measure such as HbA1c, may have an impact on
the risk of developing complications [15]. DCCT analyses
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assessing time in range (TIR) from seven-point fingerstick
data showed this had a strong association with the develop-
ment of microvascular complications including retinopathy
[17], though earlier DCCT analyses suggest that within-day
GV and mean amplitude of glucose excursions (MAGE) were
not predictive of diabetic retinopathy [18].
More widespread availability of continuous glucose moni-
toring (CGM) in recent years has led to expanding interest in
the role of glycaemic markers other than HbA1c, including
TIR, GV and MAGE, with recommendations now in place
for their use in routine diabetes management [19].
There is growing evidence from CGM that these markers
are associated with diabetic retinopathy in type 2 diabetes
[20–22]; however, less is known about their role in type 1
diabetes [23].We and others have reported that islet transplan-
tation in recipients with type 1 diabetes is associated with
diminished GV and reductions in HbA1c in association with
diminished progression of diabetic retinopathy [24, 25,
unpublished data (Reid L, Lam A, Dhillon B, Duncan K,
Ibbotson C, Sutherland A, Casey J, Koh A, Rudinsky C,
Tennant M, Malcolm A, Shapiro AMJ, Senior P, Forbes S
(2019)]. Further studies assessing the impact of GV on diabet-
ic retinopathy progression are needed.
CSII is associated with higher initial costs due to the
expense of the pump, necessary consumables and pump
education [26]. However, longer-term cost–benefit analyses
studies indicate that such costs are offset by improved
glycaemic control, enhanced quality-of-life markers and
reductions in diabetes complications, and demonstrate that
CSII is in fact a cost-effective treatment in type 1 diabetes
[26, 27]. Many cost–benefit models highlight the reduced
morbidity- and mortality-related costs secondary to reductions
in problematic hypoglycaemia associated with CSII therapy
[26], and projected cost savings related to diminished micro-
and macrovascular complications are also evident, with an
18.3% lifetime reduction in severe visual loss with CSII vs
MDI therapy [27].
The strengths of this study are that it is a relatively large
study providing real-world data on diabetic retinopathy
progression in type 1 diabetes in an adult cohort following
initiation of CSII therapy. Furthermore, diabetic retinopathy
assessment was performed within a single retinopathy screen-
ing programme. It provides reassurance that, in people with no
diabetic retinopathy or mild diabetic retinopathy at baseline,
there is no evidence of increased risk of diabetic retinopathy
progression following initiation of CSII, and there is long-
term benefit particularly in those with the highest HbA1c
compared with continued MDI therapy.
The study has several limitations. As a retrospective real-
world study, timings of retinal imaging and HbA1c collection
were not uniform for participants over the study period. In
addition, participants were not randomised to receive either
CSII or MDI therapy, resulting in potential confounding and
allocation bias. Indeed, at baseline the CSII group was signif-
icantly younger with earlier age of diabetes onset, lower base-
line HbA1c and lower diastolic BP, and lived in less socioeco-
nomically deprived areas than the MDI group. Multivariate
analyses were performed to minimise the impact of these
differences. Study entry time for the MDI group, who did
not have any specific intervention, was based on the lag time
from receiving structured education to commencing CSII ther-
apy. Although there was some variability in this lag time,
when data were reassessed using an alternative study entry
time based on the median lag time (841 days) rather thanmean
lag time (945 days) (see ESM Methods), outcomes were
unchanged, with results still showing significantly fewer reti-
nal events in the CSII group vs the MDI group (see ESM
Results and ESM Fig. 1). Retinal data were sourced from
the diabetes retinopathy screening programme, and therefore
people who had no retinal screening results could not be
assessed (7.8% CSII, 12.3% MDI). This could represent a
population of non-attenders who are not fully engaging with
aspects of their diabetes management, and as such may be at
higher risk of developing diabetic retinopathy. In addition,
few participants with advanced retinal disease, who are known
to be at the highest level of risk of diabetic retinopathy [28],
were assessed as these people leave the screening programme
to enter into a management pathway under the care of ophthal-
mologists, though numbers excluded due to receiving
ophthalmology care were similar in both groups (10.6%
CSII, 10.1% MDI). Reporting of retinopathy outcomes using
SDRGS assessment is not the gold standard, and therefore we
may have missed more subtle retinal changes that could have
been picked up by using Early Treatment Diabetic
Retinopathy Study (ETDRS) screening; however, as
SDRGS is designed to detect clinically significant changes
we feel findings are still clinically relevant. These problems
relating to the use of screening data will have affected both
groups, and therefore their impact on the study analysis was
felt to be relatively small. Glycaemic analysis was limited to
HbA1c data. Though this remains the gold standard for
glycaemic assessment, further studies using CGM will help
fully characterise the range of glycaemic factors involved in
diabetic retinopathy progression. Finally, this study was
conducted in a predominantly white population across three
diabetes centres from a single Scottish region, where a nation-
al diabetic retinopathy screening service is offered for all
people affected by diabetes. Therefore, results may not be
generalisable to all people with type 1 diabetes from other
ethnic groups, or where access to diabetic retinopathy screen-
ing is limited.
Conclusion This observational study has demonstrated
reduced diabetic retinopathy progression in a real-world popu-
lation with type 1 diabetes commenced on CSII vs those who
continued on MDI, with no evidence of early diabetic
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retinopathy worsening. Although reductions in HbA1c were
seen due to CSII therapy, these were not associated with a
reduction in diabetic retinopathy progression and as such
other glycaemic factors associatedwith CSII therapymay play
a role. Further prospective studies using CGMmay help estab-
lish if reductions in glycaemic excursions are causal in reduc-
ing the progression of diabetic retinopathy and other micro-
vascular diabetes complications.
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